These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 23789839)

  • 1. Immune alterations and immunotherapy prospects in head and neck cancer.
    Varilla V; Atienza J; Dasanu CA
    Expert Opin Biol Ther; 2013 Sep; 13(9):1241-56. PubMed ID: 23789839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines in head and neck cancer.
    Pries R; Wollenberg B
    Cytokine Growth Factor Rev; 2006 Jun; 17(3):141-6. PubMed ID: 16540364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunotherapy: a new alternative treatment for head and neck squamous cell carcinoma].
    Bron L; Romero P
    Bull Cancer; 2007 Sep; 94(9):793-7. PubMed ID: 17878099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunotherapy for head and neck squamous cell carcinoma].
    Bron L; Romero P
    Rev Med Suisse; 2006 Oct; 2(81):2216-9. PubMed ID: 17076151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The promise of immunotherapy in head and neck squamous cell carcinoma.
    Economopoulou P; Agelaki S; Perisanidis C; Giotakis EI; Psyrri A
    Ann Oncol; 2016 Sep; 27(9):1675-85. PubMed ID: 27380958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed?
    Ferris RL
    ORL J Otorhinolaryngol Relat Spec; 2004; 66(6):332-40. PubMed ID: 15668533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for head and neck squamous cell carcinoma.
    Li Q; Prince ME; Moyer JS
    Oral Oncol; 2015 Apr; 51(4):299-304. PubMed ID: 25624094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 as an immunotherapeutic target in head and neck cancer.
    Hoffmann TK; Bier H; Donnenberg AD; Whiteside TL; De Leo AB
    Adv Otorhinolaryngol; 2005; 62():151-60. PubMed ID: 15608425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.
    Cavalieri S; Rivoltini L; Bergamini C; Locati LD; Licitra L; Bossi P
    Cancer Treat Rev; 2018 Apr; 65():78-86. PubMed ID: 29574334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of suicide gene therapy in combination with immunotherapy on antitumour immune response & tumour regression in a xenograft mouse model for head & neck squamous cell carcinoma.
    Ambade AV; Joshi GV; Mulherkar R
    Indian J Med Res; 2010 Oct; 132():415-22. PubMed ID: 20966520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
    Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
    J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for head and neck cancer: the future of treatment?
    Xie X; O'Neill W; Pan Q
    Expert Opin Biol Ther; 2017 Jun; 17(6):701-708. PubMed ID: 28368668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for Head and Neck Cancer.
    Sim F; Leidner R; Bell RB
    Oral Maxillofac Surg Clin North Am; 2019 Feb; 31(1):85-100. PubMed ID: 30449528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells and HNSCC: a potential treatment option? (Review).
    Dunn G; Oliver KM; Loke D; Stafford ND; Greenman J
    Oncol Rep; 2005 Jan; 13(1):3-10. PubMed ID: 15583794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising systemic immunotherapies in head and neck squamous cell carcinoma.
    Gildener-Leapman N; Ferris RL; Bauman JE
    Oral Oncol; 2013 Dec; 49(12):1089-96. PubMed ID: 24126223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for Head and Neck Cancer.
    Sim F; Leidner R; Bell RB
    Hematol Oncol Clin North Am; 2019 Apr; 33(2):301-321. PubMed ID: 30833002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in head and neck cancer: current practice and future possibilities.
    Agada FO; Alhamarneh O; Stafford ND; Greenman J
    J Laryngol Otol; 2009 Jan; 123(1):19-28. PubMed ID: 18761763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Recchia F; Candeloro G; Di Staso M; Necozione S; Bisegna R; Bratta M; Tombolini V; Rea S
    J Immunother; 2008 May; 31(4):413-9. PubMed ID: 18391754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of an autologous cell system for immunotherapy of squamous cell carcinoma of the head and neck.
    Mayer A; Andratschke M; Pauli C; Graefe H; Kristina K; Wollenberg B
    Anticancer Res; 2005; 25(6B):4075-80. PubMed ID: 16309201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor.
    Whiteside TL
    Curr Cancer Drug Targets; 2007 Nov; 7(7):633-42. PubMed ID: 18045068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.